Tumor angiogenesis in the absence of fibronectin or its cognate integrin receptors

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Murphy, Patrick A ^a   Begum, Shahinoor ^a   Hynes, Richard O ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; ELASTIN; FIBRILLIN; FIBRONECTIN; INTEGRIN RECEPTOR; LAMININ; MATRIX PROTEIN; NID1 PROTEIN; NID2 PROTEIN; PEPTIDE; PROTEIN; RECEPTOR SUBUNIT; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN RECEPTOR; ACTIN BINDING PROTEIN; ENTACTIN; FBN1 PROTEIN, MOUSE; FIBRILLIN 1; INTEGRIN; MEMBRANE PROTEIN; NID2 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ARTICLE; BASEMENT MEMBRANE; CANCER GRAFT; CARCINOGENESIS; CELL MIGRATION; CONTROLLED STUDY; EMBRYO; EXTRACELLULAR MATRIX; GENE DELETION; IN VITRO STUDY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN BINDING; RECEPTOR BINDING; TUMOR GROWTH; ADENOCARCINOMA; ANIMAL; ENDOTHELIUM; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PANCREAS TUMOR;

ADENOCARCINOMA; ANIMALS; BASEMENT MEMBRANE; ENDOTHELIUM; EXTRACELLULAR MATRIX; FIBRILLIN-1; FIBRILLINS; FIBRONECTINS; INTEGRIN ALPHA5BETA1; INTEGRINS; MEMBRANE GLYCOPROTEINS; MICE; MICROFILAMENT PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84926226188     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120872     Document Type: Article

References (47)

1. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development. 1993 Dec; 119(4):1079-91. PMID: 8306876
2. George EL, Baldwin HS, Hynes RO. Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood. 1997 Oct 15; 90(8):3073-81. PMID: 9376588
3. Francis SE, Goh KL, Hodivala-Dilke K, Bader BL, Stark M, Davidson D, et al. Central roles of alpha5-beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arteriosclerosis, thrombosis, and vascular biology. 2002 Jun 1; 22(6):927-33. PMID: 12067900
4. Astrof S, Hynes RO. Fibronectins in vascular morphogenesis. Angiogenesis. 2009; 12(2):165-75. doi: 10.1007/s10456-009-9136-6 PMID: 19219555
5. Goh KL, Yang JT, Hynes RO. Mesodermal defects and cranial neural crest apoptosis in alpha5 integrin-null embryos. Development. 1997 Nov; 124(21):4309-19. PMID: 9334279
6. Yang JT, Bader BL, Kreidberg JA, Ullman-Cullere M, Trevithick JE, Hynes RO. Overlapping and independent functions of fibronectin receptor integrins in early mesodermal development. Developmental biology. 1999 Nov 15; 215(2):264-77. PMID: 10545236
7. Takahashi S, Leiss M, Moser M, Ohashi T, Kitao T, Heckmann D, et al. The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. The Journal of cell biology. 2007 Jul 2; 178(1):167-78. PMID: 17591922
8. Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annual review of cell and developmental biology. 2010; 26:397-419. doi: 10.1146/annurev-cellbio-100109-104020 PMID: 20690820
9. Zhou X, Rowe RG, Hiraoka N, George JP, Wirtz D, Mosher DF, et al. Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. Genes & development. 2008 May 1; 22(9):1231-43.
10. Stratman AN, Malotte KM, Mahan RD, Davis MJ, Davis GE. Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood. 2009 Dec 3; 114(24):5091-101. doi: 10.1182/blood-2009-05-222364 PMID: 19822899
11. van der Flier A, Badu-Nkansah K, Whittaker CA, Crowley D, Bronson RT, Lacy-Hulbert A, et al. Endothelial alpha5 and alphav integrins cooperate in remodeling of the vasculature during development. Development. 2010 Jul; 137(14):2439-49. doi: 10.1242/dev.049551 PMID: 20570943
12. Turner CJ, Badu-Nkansah K, Crowley D, van der Flier A, Hynes RO. Integrin-alpha5beta1 is not required for mural cell functions during development of blood vessels but is required for lymphatic-blood vessel separation and lymphovenous valve formation. Developmental biology. 2014 Aug 15; 392 (2):381-92. doi: 10.1016/j.ydbio.2014.05.006 PMID: 24858485
13. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. The Lancet Oncology. 2014 Sep; 15(10):1100-8. doi: 10.1016/S1470-2045(14)70379-1 PMID: 25163906
14. Schaffner F, Ray AM, Dontenwill M. Integrin alpha5beta1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers. 2013; 5(1):27-47. doi: 10.3390/cancers5010027 PMID: 24216697
15. Mateo J, Berlin J, de Bono JS, Cohen RB, Keedy V, Mugundu G, et al. A first-in-human study of the anti-alpha5beta1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2014 Sep 12.
16. Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature medicine. 2009 Apr; 15(4):392-400. doi: 10.1038/nm.1941 PMID: 19305413
17. Taverna D, Hynes RO. Reduced blood vessel formation and tumor growth in alpha5-integrin-negative teratocarcinomas and embryoid bodies. Cancer research. 2001 Jul 1; 61(13):5255-61. PMID: 11431367
18. Taverna D, Ullman-Cullere M, Rayburn H, Bronson RT, Hynes RO. A test of the role of alpha5 integrin/fibronectin interactions in tumorigenesis. Cancer research. 1998 Feb 15; 58(4):848-53. PMID: 9485045
19. Astrof S, Crowley D, George EL, Fukuda T, Sekiguchi K, Hanahan D, et al. Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Molecular and cellular biology. 2004 Oct; 24(19):8662-70. PMID: 15367684
20. von Au A, Vasel M, Kraft S, Sens C, Hackl N, Marx A, et al. Circulating fibronectin controls tumor growth. Neoplasia. 2013 Aug; 15(8):925-38. PMID: 23908593
21. Lacy-Hulbert A, Smith AM, Tissire H, Barry M, Crowley D, Bronson RT, et al. Ulcerative colitis and autoimmunity induced by loss of myeloid alphav integrins. Proceedings of the National Academy of Sciences of the United States of America. 2007 Oct 2; 104(40):15823-8. PMID: 17895374
22. Sakai T, Johnson KJ, Murozono M, Sakai K, Magnuson MA, Wieloch T, et al. Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nature medicine. 2001 Mar; 7(3):324-30. Epub 2001/03/07. eng. PMID: 11231631
23. Wang Y, Nakayama M, Pitulescu ME, Schmidt TS, Bochenek ML, Sakakibara A, et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature. 2010 May 27; 465(7297):483-6. doi: 10.1038/nature09002 PMID: 20445537
24. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007 Feb 8; 445(7128):661-5. PMID: 17251932
25. Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007 Sep; 45(9):593-605. PMID: 17868096
26. Adams TE, Alpert S, Hanahan D. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells. Nature. 1987 Jan 15-21; 325(6101):223-8. PMID: 3543686
27. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature. 1985 May 9-15; 315(6015):115-22. PMID: 2986015
28. Hager JH, Hodgson JG, Fridlyand J, Hariono S, Gray JW, Hanahan D. Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas. Cancer research. 2004 Apr 1; 64(7):2406-10. PMID: 15059892
29. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996 Aug 9; 86(3):353-64. PMID: 8756718
30. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer cell. 2002 Mar; 1(2):193-202. PMID: 12086877
31. Xie L, Duncan MB, Pahler J, Sugimoto H, Martino M, Lively J, et al. Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proceedings of the National Academy of Sciences of the United States of America. 2011 Jun 14; 108(24): 9939-44. doi: 10.1073/pnas.1105041108 PMID: 21622854
32. Murphy PA, Hynes RO. Alternative Splicing of Endothelial Fibronectin Is Induced by Disturbed Hemodynamics and Protects Against Hemorrhage of the Vessel Wall. Arteriosclerosis, thrombosis, and vascular biology. 2014 Jun 5.
33. Moriya K, Bae E, Honda K, Sakai K, Sakaguchi T, Tsujimoto I, et al. A fibronectin-independent mechanism of collagen fibrillogenesis in adult liver remodeling. Gastroenterology. 2011 May; 140(5):1653-63. doi: 10.1053/j.gastro.2011.02.005 PMID: 21320502
34. Kawelke N, Vasel M, Sens C, Au A, Dooley S, Nakchbandi IA. Fibronectin protects from excessive liver fibrosis by modulating the availability of and responsiveness of stellate cells to active TGF-beta. PloS one. 2011; 6(11):e28181. doi: 10.1371/journal.pone.0028181 PMID: 22140539
35. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5-beta1 with the central cell-binding domain of fibronectin. The American journal of pathology. 2000 Apr; 156(4):1345-62. PMID: 10751360
36. Bhaskar V, Fox M, Breinberg D, Wong MH, Wales PE, Rhodes S, et al. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Investigational new drugs. 2008 Feb; 26(1):7-12. PMID: 17786386
37. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nature reviews Cancer. 2008 Aug; 8(8):604-17. doi: 10.1038/nrc2353 PMID: 18497750
38. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, et al. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. Journal of translational medicine. 2007; 5:61. PMID: 18042290
39. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, et al. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nature medicine. 2002 Jan; 8(1):27-34. PMID: 11786903
40. Hodivala-Dilke K. alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Current opinion in cell biology. 2008 Oct; 20(5):514-9. doi: 10.1016/j.ceb.2008.06.007 PMID: 18638550
41. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nature medicine. 2002 Sep; 8(9): 918-21. PMID: 12205444
42. Naba A, Clauser KR, Whittaker CA, Carr SA, Tanabe KK, Hynes RO. Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver. BMC cancer. 2014; 14:518. doi: 10.1186/1471-2407-14-518 PMID: 25037231
43. Naba A, Clauser KR, Lamar JM, Carr SA, Hynes RO. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. eLife. 2014; 3:e01308. doi: 10.7554/eLife.01308 PMID: 24618895
44. Naba A, Hoersch S, Hynes RO. Towards definition of an ECM parts list: an advance on GO categories. Matrix biology: journal of the International Society for Matrix Biology. 2012 Sep-Oct; 31(7-8):371-2.
45. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Molecular & cellular proteomics: MCP. 2012 Apr; 11(4):M111 014647.
46. Hynes RO, Naba A. Overview of the matrisome - an inventory of extracellular matrix constituents and functions. Cold Spring Harbor perspectives in biology. 2012 Jan; 4(1):a004903. doi: 10.1101/cshperspect.a004903 PMID: 21937732
47. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proceedings of the National Academy of Sciences of the United States of America. 2012 Sep 11; 109(37):E2441-50. doi: 10.1073/pnas.1212021109 PMID: 22891335